Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
November 08 2023 - 7:00AM
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company
developing transformational treatments for patients with serious
metabolic disease marked by high unmet medical need, today
announced management will present at the following investor
conferences this month:
- Jefferies London Healthcare Conference: Fireside chat on
Wednesday, November 15 at 5:00 p.m. GMT
- Evercore ISI HealthCONx Conference: Fireside chat on Wednesday,
November 29 at 7:30 a.m. ET
Live webcasts of the Company presentations will be available
through the investor relations section of the Company's website at
www.akerotx.com. Following the live webcasts, archived replays will
be available on the Company's website.
About Akero TherapeuticsAkero Therapeutics is a
clinical-stage company developing transformational treatments for
patients with serious metabolic diseases marked by high unmet
medical need, including NASH, a disease without any approved
therapies. Akero's lead product candidate, EFX, is a differentiated
Fc-FGF21 fusion protein that has been engineered to mimic the
balanced biological activity profile of native FGF21, an endogenous
hormone that alleviates cellular stress and regulates metabolism
throughout the body. EFX is designed to offer convenient
once-weekly subcutaneous dosing. EFX is currently being evaluated
in two ongoing, 96-week Phase 2b clinical trials: the HARMONY study
in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the
SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis,
compensated). Screening in the first two of three Phase 3 clinical
trials began in September 2023, the SYNCHRONY Histology study and
the SYNCHRONY Real-World study. Akero is headquartered in South San
Francisco. Visit us at akerotx.com and follow us on
LinkedIn and Twitter for more information.
Investor Contact: Austin
Murtagh212.698.8696IR@akerotx.com
Media Contact: Sarah
O’Connell732.456.0092soconnell@vergescientific.com
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Jul 2023 to Jul 2024